| abstract |
Disclosed are oligonucleotides which hybridize to a portion of respiratory syncytial virus (RSV) genomic RNA under physiological conditions, and, in doing so, inhibit viral replication. Also disclosed are pharmaceutical compositions and methods useful for inhibiting and treating RSV infection and including at least one or two of these oligonucleotides, or at least one of these oligonucleotides and ribavirin. |